The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Smoking, nicotine and Parkinson's disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,396
Presynaptic nicotinic ACh receptors
Wonnacott, S. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10073-4 · Cited by 1,308
Nicotinic Receptors in the Development and Modulation of CNS Synapses
Role, L. W., & Berg, D. K. (1996) · Neuron · doi:10.1016/s0896-6273(00)80134-8 · Cited by 762
Cytokines and the nervous system I: expression and recognition
Hopkins, S. J., & Rothwell, N. J. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)80029-2 · Cited by 751
Inhibition of monoamine oxidase B in the brains of smokers
Fowler, J. S., Volkow, N. D., Wang, G.-J., Pappas, N., Logan, J., MacGregor, R., Alexoff, D., Shea, C., Schlyer, D., Wolf, A. P., et al. (1996) · Nature · doi:10.1038/379733a0 · Cited by 656
The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living
Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., & Richardson, R. J. (1998) · Neurology · doi:10.1212/wnl.50.5.1346 · Cited by 639
Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum
Zhou, F.-M., Liang, Y., & Dani, J. A. (2001) · Nature Neuroscience · doi:10.1038/nn769 · Cited by 585
PRESYNAPTIC IONOTROPIC RECEPTORS AND THE CONTROL OF TRANSMITTER RELEASE
MacDermott, A. B., Role, L. W., & Siegelbaum, S. A. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.443 · Cited by 576
Cited by
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Mammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Brain nicotinic acetylcholine receptors: native subtypes and their relevance
Gotti, C., Zoli, M., & Clementi, F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.07.004 · Cited by 882
Guidelines on nicotine dose selection for in vivo research
Matta, S. G., Balfour, D. J., Benowitz, N. L., Boyd, R. T., Buccafusco, J. J., Caggiula, A. R., Craig, C. R., Collins, A. C., Damaj, M. I., Donny, E. C., et al. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0441-0 · Cited by 824
“The transcripts for the α2 through α7 and β2 through β4 nAChR subunits have been identified and expressed in nonhuman primate neuronal tissues, with numerous receptor subtypes present in multiple brain regions (Cimino et al. 1992; Han et al. 2000, 2003; Quik 2004; Quik et al. 2000, 2001, 2005).”
BackgroundSelf-citationMeta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 778
Neurodegenerative Diseases: An Overview of Environmental Risk Factors
Brown, R. C., Lockwood, A. H., & Sonawane, B. R. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7567 · Cited by 512
Stress-Response Hormesis and Aging: “That which Does Not Kill Us Makes Us Stronger”
Gems, D., & Partridge, L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.01.001 · Cited by 498
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Advances in the treatment of Parkinson's disease
Singh, N., Pillay, V., & Choonara, Y. E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.009 · Cited by 394
Pooled Analysis of Tobacco Use and Risk of Parkinson Disease
Ritz, B., Ascherio, A., Checkoway, H., Marder, K. S., Nelson, L. M., Rocca, W. A., Ross, G. W., Strickland, D., Van Den Eeden, S. K., & Gorell, J. (2007) · Archives of Neurology · doi:10.1001/archneur.64.7.990 · Cited by 370
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Oertel, W., & Schulz, J. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13750 · Cited by 369
Calabresi, P., Picconi, B., Parnetti, L., & Di Filippo, M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70600-7 · Cited by 338
Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study
Dick, F. D., De Palma, G., Ahmadi, A., Scott, N. W., Prescott, G. J., Bennett, J., Semple, S., Dick, S., Counsell, C., Mozzoni, P., et al. (2007) · Occupational and Environmental Medicine · doi:10.1136/oem.2006.027003 · Cited by 325
Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein
Uversky, V., & Eliezer, D. (2009) · Current Protein & Peptide Science · doi:10.2174/138920309789351921 · Cited by 322
Genetics of Parkinson's disease and parkinsonism
Hardy, J., Cai, H., Cookson, M. R., Gwinn‐Hardy, K., & Singleton, A. (2006) · Annals of Neurology · doi:10.1002/ana.21022 · Cited by 303
Serum uric acid levels and the risk of Parkinson disease
de Lau, L. M. L., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20663 · Cited by 301
Does tobacco use cause psychosis? Systematic review and meta-analysis
Gurillo, P., Jauhar, S., Murray, R. M., & MacCabe, J. H. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00152-2 · Cited by 300
Novel pharmacological targets for the treatment of Parkinson's disease
Schapira, A. H. V., Bezard, E., Brotchie, J., Calon, F., Collingridge, G. L., Ferger, B., Hengerer, B., Hirsch, E., Jenner, P., Novère, N. L., et al. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2087 · Cited by 298
Neural Activity Controls the Synaptic Accumulation of α-Synuclein
Fortin, D. L., Nemani, V. M., Voglmaier, S. M., Anthony, M. D., Ryan, T. A., & Edwards, R. H. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2922-05.2005 · Cited by 271
The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery
Dutta, G., Zhang, P., & Liu, B. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00616.x · Cited by 235
Lester, H. A., Xiao, C., Srinivasan, R., Son, C. D., Miwa, J., Pantoja, R., Banghart, M. R., Dougherty, D. A., Goate, A. M., & Wang, J. C. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9090-7 · Cited by 163
Nicotine and Parkinson's disease: implications for therapy
Quik, M., O'Leary, K., & Tanner, C. M. (2008) · Movement Disorders · doi:10.1002/mds.21900 · Cited by 154
Self-citationInflammatory bowel diseases and Parkinson's disease
Brudek, T. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191729 · Cited by 139
Maskos, U. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.5 · Cited by 139
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys
Quik, M., Cox, H., Parameswaran, N., O'Leary, K., Langston, J. W., & Di Monte, D. (2007) · Annals of Neurology · doi:10.1002/ana.21203 · Cited by 133
Self-citationTo die or grow: Parkinson's disease and cancer
WEST, A., DAWSON, V, & DAWSON, T. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.05.002 · Cited by 117
Lai, A., Parameswaran, N., Khwaja, M., Whiteaker, P., Lindstrom, J. M., Fan, H., McIntosh, J. M., Grady, S. R., & Quik, M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006429 · Cited by 112
Self-citationKawamata, J., & Shimohama, S. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110173 · Cited by 111
The Neuronal Pathways Mediating the Behavioral and Addictive Properties of Nicotine
Balfour, D. J. K. (2009) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-69248-5_8 · Cited by 99
Liu, H., Hao, Y., Kaneko, Y., Ouyang, X., Zhang, Y., Xu, L., Xue, Z., & Liu, Z. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01989.x · Cited by 97
dos Santos, E. F., Busanello, E. N. B., Miglioranza, A., Zanatta, Â., Barchak, A. G., Vargas, C. R., Saute, J., Rosa, C., Carrion, M. J., Camargo, D., et al. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-009-9139-4 · Cited by 76
Khwaja, M., McCormack, A., McIntosh, J. M., Di Monte, D. A., & Quik, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04177.x · Cited by 54
Self-citationMarks, M. J., Whiteaker, P., & Collins, A. C. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025338 · Cited by 53
Visanji, N. P., Mitchell, S. N., O'Neill, M. J., & Duty, S. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.07.013 · Cited by 25
Metadata
- Authors
- Quik, M.
- Venue
- Trends in Neurosciences
- Publisher
- Elsevier BV
- Published
- 2004-09
- Volume
- 27
- Issue
- 9
- Pages
- 561-568
- ISSN
- 0166-2236 (ISSN-L)
- OpenAlex
- W2004747758
- Cited by
- 324
- References
- 74
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.